Back to articles

Additional efficacy and safety data for tiotropium released


A large cohort study involving more than 40,000 patients concluded that use of tiotropium (Spiriva HandiHaler—Boehringer Ingelheim, Pfizer) in combination with an inhaled corticosteroid (ICS) and long-acting beta-2 agonist (LABA) was associated with a decreased risk of death, exacerbations, and hospitalizations compared with a treatment regimen that only contains an ICS plus LABA.


Lee TA et al. Arch Intern Med. 2009;169:1403–10.

Singh S et al. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease. JAMA. 2008;300:1439–50.